This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
7 Nasdaq ETFs to Play the Index's Winning Momentum
by Sanghamitra Saha
The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
Nasdaq Hits 13,000 for the First Time: ETFs to Bet On
by Sanghamitra Saha
The year 2020 can easily be fully attributed to the Nasdaq as the tech-heavy index gained jumped about 44%. However, the index many more reasons to rally this year too.
Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study updates from Moderna (MRNA) and other regulatory updates.
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study
by Zacks Equity Research
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis
by Zacks Equity Research
Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
by Zacks Equity Research
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -95.74% and -26.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Arcturus Therapeutics (ARCT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -3.77% and -54.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Arcturus Therapeutics (ARCT)?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.
All You Need to Know About Arcturus Therapeutics (ARCT) Rating Upgrade to Buy
by Zacks Equity Research
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Arcturus Therapeutics (ARCT) Stock a Solid Choice Right Now?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -55.10% and -34.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcturus Therapeutics (ARCT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
by Zacks Equity Research
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
by Zacks Equity Research
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
by Zacks Equity Research
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).